T Cell Vaccination in Patients With Progressive Multiple Sclerosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dimitrios Karussis, Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01448252
First received: October 5, 2011
Last updated: October 6, 2011
Last verified: October 2011
  Purpose

This is a double blind phase I-II clinical trial with multiple autologous T cell vaccinations using T cell lines reactive to 9 different myelin peptides of MBP, MOG and PLP, in patients with relapsing progressive Multiple Sclerosis.


Condition Intervention Phase
Multiple Sclerosis
Biological: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)
Biological: T cell vaccination
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • EDSS changes [ Time Frame: one year ] [ Designated as safety issue: No ]
    Follow up in changes in the EDSS score

  • Relapse rate of MS [ Time Frame: one year follow up ] [ Designated as safety issue: No ]
    recording of the relapses of MS during the year of the study and the prior to the study

  • PASAT test [ Time Frame: one year ] [ Designated as safety issue: No ]
    recording of the performance in the PASAT test during the one year of the study

  • Nine hole PEG test [ Time Frame: one year ] [ Designated as safety issue: No ]
    recording of the performance in the Nine hole PEG test test during the one year of the study

  • timed ten meter walking [ Time Frame: one year ] [ Designated as safety issue: No ]
    recording of the performance in the timed ten meter walking test during the one year of the study


Secondary Outcome Measures:
  • Quantitative MRI evaluation [ Time Frame: one year ] [ Designated as safety issue: No ]
    the burden of T2 lesions load, of the hypo-intense T1 lesions, of the Gadolinium enhancing lesions and of the brain atrophy will be evaluated at the end of the study and compared to the baseline values


Estimated Enrollment: 30
Study Start Date: May 2002
Study Completion Date: March 2009
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: TCV
multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
Biological: T cell vaccination
Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
Sham Comparator: Placebo
saline injections subcutaneously at the same 4 time points with active treatment
Biological: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)
multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
Other Name: multiple subcutenous injections of saline at days 1, 30,90,180.

Detailed Description:

This trial is a phase I/II double-blind controlled clinical trial designed to evaluate the safety and clinical efficacy of multiple autologous T-cell vaccinations (on days 1, 30, 90 and 180) in progressive MS patients which showed severe progression/deterioration in the functional status (at least, one degree in the EDSS scale) during the last year, or at least one severe relapse. The patients will be from our MS clinic and will be randomized (by computer) into two groups according to: age, disease duration, disease severity and progression rate. One group (2/3 of the patients) will receive the active treatment, i.e. TCV, and the other group (1/3 of the patients) will receive sham treatment (injection of sterile normal saline). The treating nurse, the treating physician, the examining neurologist (the one who will perform the neurological evaluation) and the patient will be blinded for the treatment.

OBJECTIVES AND SIGNIFICANCE OF THE TRIAL

A. To develop a new cell therapeutic modality for treating MS patients using attenuated autologous anti-MBP, anti-PLP and anti-MOG autoreactive T-cells as vaccines. The immune response induced by this vaccination will be directed specifically against the T-cells attacking the patient's nerve system (specifically the myelin sheath).

B. To study and characterize these autoreactive T-cells in MS patients. The number and function of such cells in the course of the relapse of the disease, as well as during the periods of remissions, will be studied.

C. To study the clinical efficacy of T-cell vaccination with attenuated anti-MBP and anti-MOG autologous T-cells on MS. The parameters to be examined will include: change in the disability status (by the EDSS disability scale, as well as by ambulation index and several other functional tests), the change in the relapse rate and in the timed 10-meters walking test, the PASAT test and the 9-hole peg test. MRI parameters will represent additional endpoints and will include: the changes in the total burden of the disease and in the quantity of irreversible damage (cortical atrophy and axonal loss). In addition, the effects of this treatment on the immune responses (i.e. number and proportion of activated lymphocytes, number and proportion of anti-myelin reactive lymphocytes in the peripheral blood and IgG antibody levels in the cerebrospinal fluid) will be evaluated in the treated MS patients.

The significance and importance of the study are outlined as follows:

  1. It offers a new approach for the treatment of MS.
  2. This approach has the advantage of being devoid of toxic or general immunosuppressive effects.
  3. The study will pave the way for further studies that will improve our understanding of the mechanisms of the host immune response in MS and of the involvement of the MBP, PLP and MOG myelin proteins in the initiation of the auto-reactive immune response and of clinical MS.
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinically definite MS (according to Poser's criteria) of the relapsing-progressive type (RPMS).
  2. Age: 18-60.
  3. EDSS: 3.0 to 7.0.
  4. Disease duration: > 1 year.
  5. Evidence of disease progression of 1 degree in the EDSS scale, or at least two severe relapses (requiring hospitalization and treatment) during the year prior to inclusion.
  6. MRI of the brain with at least 5 lesions in the white matter (T2 imaging).
  7. Failure to benefit from other existing treatments according to the guidelines of the Israeli Ministry of Health.

Exclusion Criteria:

  1. Patients with other systemic active disease.
  2. Patients who had been treated with immunosuppressive drugs during the 3-6 months depending on the cytotoxicity of the medication used prior to the inclusion.
  3. Patients who previously received cellular immunotherapy or who are participating in other experimental protocols.
  4. Pregnancy; Pregnant women or women who do not use efficacious contraception (oral contraception, or intra-uterine device).
  5. Patients with an additional autoimmune condition unrelated to MS or significant allergy.
  6. Patients who cannot fully understand the treatment protocol or are unable to sign the informed consent, or in whom the clinician believes that a follow-up period of at least 12 months will not be possible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01448252

Locations
Israel
Dept of Neurology,Hadassah ein-Kerem
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Dimitrios Karussis, Prof. Hadassah Medical Organizatin
Study Director: Rivka Abulafia-Lapid, PhD Hadassah Medical Organization
  More Information

No publications provided by Hadassah Medical Organization

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dimitrios Karussis, Head, Multiple Sclerosis Center, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT01448252     History of Changes
Other Study ID Numbers: TCV-HMO-CTIL, 27-15.15.00
Study First Received: October 5, 2011
Last Updated: October 6, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by Hadassah Medical Organization:
T cell vaccination
Immunotherapy
Tolerance
safety
clinical efficacy

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on October 19, 2014